palivizumab
Sign in to saveAlso known as Synagis Abbosynagis, MEDI-493, anti-RSV
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.
In the Vinony graph
Vinony's link graph records 137 inbound references to palivizumab, and connects out to casirivimab/imdevimab, AZD7442 and respiratory syncytial virus.
It is catalogued under topics including Biotechnology, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Vinony links it to 15 Wikipedia language editions.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 1998
- Admin. routes
- parenteral
- Indications
- respiratory system disease, congenital heart disease, Respiratory Syncytial Virus Infection, bronchopulmonary dysplasia
via ChEMBL · EBI
Research
1,515 papers- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.Pediatrics · 2024
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.The Cochrane database of systematic reviews · 2021
- Palivizumab.Drugs · 1999
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.The Cochrane database of systematic reviews · 2025
- Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.Pediatrics · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- palivizumab
- subject has role
- monoclonal antibody
- medical condition treated
- heart disease
- has characteristic
- biopharmaceutical
Sources (3)
via Wikidata · CC0
~7 min read
Encyclopedic overview
17 sectionsContents
- Medical use
- RSV Prophylaxis
- RSV Prophylaxis Target Groups
- RSV Treatment
- Contraindications
- Side effects
- Pharmacology
- Pharmacodynamics
- Mechanism of action
- Pharmacokinetics
- Absorption
- Distribution
- Clearance
- Society and Culture
- Cost
- History
- References
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.
The most common side effects include fever and rash.
Excerpted from Wikipedia’s “palivizumab” article, available under the CC BY-SA 4.0 licence.
Available in 15 languages
- Español
- Français
- Deutsch
- 中文
- 日本語
- Português
- Italiano
- العربية
- Bahasa Indonesia
- Odia
- Serbian
- Serbian (Latin)
- Tiếng Việt
- Ukrainian
via Wikidata sitelinks · CC0